NEWARK, Del.--(BUSINESS WIRE)--SDI (Strategic Diagnostics Inc., NASDAQ:SDIX), a leading provider of biotechnology-based products and services for a broad range of life science, food safety, and industrial applications, today announced it has been selected again by Science Applications International Corporation - Frederick (SAIC-F) to develop monoclonal antibodies for the National Cancer Institute’s “Clinical Proteomic Technologies for Cancer” initiative (CPTC: http://proteomics.cancer.gov). The SDI monoclonal antibodies will serve as reference reagents for the scientific cancer community.
